| Revenue growth | Consolidated revenue flat at ₹345.4 cr; standalone exports down 23%. |
|---|---|
| Margins | EBITDA margins expanding significantly through high-margin complex generics and branded products. |
| Order book | Order book stands at ₹171 cr, supporting standalone recovery expectations. |
| Demand visibility | Strong order book of ₹171 cr provides visibility for FY27 growth. |
| Management confidence | Balanced; focused on inflection point following regulatory clearances and facility upgrades. |
Growth
Consolidated EBITDA jumped 485% to ₹15.8 cr, driven by Inoxxel narrowing losses. Verineum turned profitable, growing 13.7% YoY.
Outlook
FY27 guidance: 10-15% growth for standalone, 35-45% for Inoxxel, and 20-25% for Verineum with expanded margins.
Risks
Standalone business faces temporary disruption from plant upgrades and upcoming PIC/S and EUGMP audits in FY27.
Earnings Call filed with BSE, BSE: 541096. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,842.35
- Market cap
- ₹1,270 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -82.4×Sector 47.4×
- Promoter holding
- 67.20%+0.03% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Board Meeting Date
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Management Change
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Dividend
Bharat Parenterals Limited has fixed September 12, 2026, as the record date to determine shareholder eligibility for the dividend for FY 2025-26.
Bharat Parenterals Annual Report
Bharat Parenterals Limited has submitted its Annual Report for the financial year 2025-26. The report includes the notice for the 33rd Annual General Meeting.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited has scheduled its 33rd Annual General Meeting on September 19, 2026, to discuss financial results, dividend declaration, and director reappointments.